IMU-838 (30 mg/day) + IMU-838 (45 mg/day) + Placebo + IMU-838 (10 mg/day)
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Trial Timeline
Jan 28, 2019 → Dec 1, 2029
NCT ID
NCT03846219About IMU-838 (30 mg/day) + IMU-838 (45 mg/day) + Placebo + IMU-838 (10 mg/day)
IMU-838 (30 mg/day) + IMU-838 (45 mg/day) + Placebo + IMU-838 (10 mg/day) is a phase 2 stage product being developed by Immunic for Relapsing-Remitting Multiple Sclerosis (RRMS). The current trial status is active. This product is registered under clinical trial identifier NCT03846219. Target conditions include Relapsing-Remitting Multiple Sclerosis (RRMS).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03846219 | Phase 2 | Active |
Competing Products
20 competing products in Relapsing-Remitting Multiple Sclerosis (RRMS)